Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Harvest Technologies
ClinicalTrials.gov Identifier:
NCT01245335
First received: November 18, 2010
Last updated: June 25, 2014
Last verified: June 2014

November 18, 2010
June 25, 2014
May 2011
November 2014   (final data collection date for primary outcome measure)
Amputation Free Survival [ Time Frame: Six Months ] [ Designated as safety issue: Yes ]
Survival without a major (above the ankle) amputation
Same as current
Complete list of historical versions of study NCT01245335 on ClinicalTrials.gov Archive Site
  • Change In Rutherford Classification [ Time Frame: Six Months ] [ Designated as safety issue: No ]
    Change in the subjects clinical status as measured by Rutherford Classification
  • Change in Pain [ Time Frame: Six Months ] [ Designated as safety issue: No ]
    Change in Subjects perception of pain as measured on a 100 mm visual analog scale
Same as current
Not Provided
Not Provided
 
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease

Critical Limb Ischemia prevents the legs and feet from receiving oxygen and nutrients needed for proper function. This severe lack of blood flow can lead to painful legs while walking or at rest and can result in foot sores, ulcers, gangrene, and even amputation. The purpose of this study is to determine if injections of concentrated bone marrow into damaged tissues will result in improved blood flow. If successful, this treatment could improve blood flow to the lower limb, reduce pain, and reduce the frequency of limb amputations.

Bone marrow aspirate is collected and processed by centrifugation to remove red blood cells. The resulting concentrate of cells is injected into ischemic tissues of the lower limb. The purpose of this study is to determine if injections of concentrated bone marrow nucleated cells into ischemic tissues will result in vasculogenesis.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Critical Limb Ischemia
  • Device: BMAC injection
    Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC) prepared with the SmartPReP2 BMAC System
  • Device: Placebo injection
    Injection of placebo into ischemic tissue of the lower extremity
  • Active Comparator: BMAC Treatment
    Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC) prepared with the SmartPReP2 BMAC System
    Intervention: Device: BMAC injection
  • Placebo Comparator: Placebo Injection
    Injection of placebo into ischemic tissue of the lower extremity
    Intervention: Device: Placebo injection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
210
November 2016
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has Peripheral Arterial Occlusive Disease (PAOD) with clinical Rutherford Category 5 disease, as defined in the reporting standards adopted by the Society of Vascular Surgeons(table 1); Minor Tissue loss-focal gangrene with diffuse pedal ischemia
  • Patient meets at least one of the following diagnostic criteria in the study limb:

    • Ankle artery occlusion pressure absolute ≤60 mmHg or ABI ≤0.6
    • Toe artery occlusive pressure < 50mm Hg or TBI ≤0.6
  • There is no reasonable open surgical or endovascular revascularization option as determined by the treating vascular specialist. Factors that may contribute to the determination of inoperability may include:

    • Anatomical considerations
  • No outflow targets
  • No appropriate conduit (i.e. vein for bypass)
  • Long segment occlusions or calcified lesions that predict poor outcome with endovascular approaches.

    • High risk medical conditions i.e. Unstable cardiac disease.
    • History of prior failed revascularization attempts
  • The Patient's case was reviewed at the treating institution's Multidisciplinary Vascular Conference where the patient's status as a poor candidate for conventional therapies was confirmed.
  • Age ≥18 years and ability to understand the planned treatment
  • Subject has read and signed the IRB approved Informed Consent form
  • Patients for whom the following medication(s) is prescribed must have a one month stable baseline therapy prior to enrollment: Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or blood pressure medication. If any of these medications are not prescribed notation of the reason for omission is to be provided.
  • Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 2.5 mg / dL, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery.

Exclusion Criteria:

  • Life expectancy <6 months due to concomitant illnesses
  • History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation
  • Terminal renal failure with existing dependence on dialysis or serum creatinine >2.5 mg/dL
  • Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
  • Poorly controlled diabetes mellitus (HgbA1C>10%)
  • Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5
  • Life-threatening complications of the ischemia necessitating immediate amputation
  • Uncorrected occlusion of the common or external iliac artery on index side
  • Absence of any pulsatile Doppler flow below the ankle.
  • Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6).
  • Ulceration with exposed bone proximal to the distal metatarsal heads (ie. heel or mid foot)
  • Active clinical infection or infection being treated by antibiotics within one week of enrollment
  • Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day).
  • Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method.
  • Underwent a major open cardiovascular surgical procedure (carotid endarterectomy, arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or a myocardial infarction within the 3 months prior to randomization
  • Underwent a successful or partially successful endovascular intervention for peripheral arterial occlusive disease. (ie. Aorta, iliac, femoral, popliteal, or tibial artery angioplasty, stenting, or atherectomy) within the prior 3 months.
  • Endovascular coronary intervention (ie. Angioplasty, atherectomy, stenting) within 1 month prior to randomization.
  • Underwent a failed attempt for endovascular revascularization during the prior 1 month. For the purpose of this exclusion criteria an endovascular procedure is considered a failure if:

    1. The procedure is diagnostic only with no intervention performed, (for example in the case where wire crossing can not be obtained).
    2. The treated artery recoils, thromboses, or dissects resulting in occlusion of the treated arterial segment, documented by intraoperative imaging. Note that endovascular procedures with suboptimal results but not meeting criteria 1 or 2 above may qualify for inclusion after 3 months as in #16 above.
  • Cerebrovascular accident within 6 months prior to randomization.
  • Treatment with topical growth factors or hyperbaric oxygen (HBO) within 30 days, or systemic growth factor treatment within 6 months of enrollment.
  • Known hypersensitivity to heparin; or history of heparin-induced thrombocytopenia (HIT).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01245335
CLI-2011-1
Yes
Harvest Technologies
Harvest Technologies
Not Provided
Principal Investigator: Mark Iafrati, MD Tufts Medical Ctr
Harvest Technologies
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP